Dr. David K. Buchbinder, Pediatric Hematology

Dr. David K. Buchbinder, Pediatric Hematology
  • David K Buchbinder MD
  • Appointments:
    888-770-2462
  • Office: 714-509-8459
  • Specialties: Hematology, Pediatrics
  • Board Certified: Pediatrics, Pediatric Hematology/Oncology

Dr. David Buchbinder’s clinical and research interests are in hematopoietic cell transplantation for non-malignant disorders, in addition to investigating and understanding psychosocial impact of chronic illness in patients and families. He is currently working with his colleagues at CHOC and the University of California, Irvine to look at the impact of late occurring toxicities of hematopoietic and malignant diseases.

Dr. Buchbinder is board certified in pediatrics and pediatric hematology-oncology. Prior to joining CHOC, Dr. Buchbinder attended medical school at the Medical College of Wisconsin in Milwaukee. He performed his pediatric internship and residency and completed his fellowship training in pediatric hematology and oncology at the University of California, Los Angeles.

Clinical Interests

Understanding the impact of non-malignant blood disorders on families.

Research Focus

Hematopoietic cell transplantation for non-malignant disorders, impact of late occurring toxicities of hematopoietic and malignant diseases.

David K Buchbinder MD is on staff at CHOC Hospital in Orange .

Locations

CHOC Clinic
1201 W. La Veta Ave. Building: CHOC Clinic
Orange, CA 92868
phone: 888-770-2462
fax: 855-246-2329

St Joseph Hospital
1100 W Stewart Dr.
Orange, CA 92868

Education

  • Medical School
    Medical College of Wisconsin, Milwaukee, Wisconsin
  • Pediatric Hematology and Oncology Fellowship
    Mattel Children’s Hospital at UCLA, Los Angeles, California
  • Pediatric Residency
    Mattel Children’s Hospital at UCLA, Los Angeles, California

Administrative Appointments

  • Hematology, CHOC Specialists

Editorial Boards

  • Annals of Oncology
  • Cancer
  • Psychooncology

Honors and Awards

  • 2009 Stein Oppenheimer Endowment Award
  • 2009-2010 ASCO Young Investigator Award

Presentations and Abstracts

Compound Heterozygous RAG1 Mutations In A Patient With Common Variable Immunodeficiency. CIS Meeting. 2014; Abstract.

Psychosocial Outcomes of Siblings of Pediatric Stem Cell Transplant Survivors. ASCO Meeting. 2014; Abstract.

Successful Treatment of Secondary Graft Failure Following Unrelated Cord Blood Transplant with Hematopoietic Growth Factors in a Pediatric Patient with Fanconi Anemia. BMT Tandem Meetings. 2015; Abstract.

Pulmonary Hypertension in Two Patients with CANDLE syndrome. CIS Meeting. 2015; Abstract.

Tobacco Use Among Siblings of Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study. American Society of Pediatric Hematology Oncology Meeting. 2015; Abstract.

Large Granular Lymphocyte Leukemia Presenting in Adolescence. American Society of Pediatric Hematology Oncology Meeting. 2015; Abstract.

Psychosocial Health Among Adolescent and Young Adult Brain Tumor Survivors. ISOQOL Meeting. 2015; Abstract.

Survival and Late Effects of Children Undergoing Myeloablative Allogeneic HCT at Less Than Three Years of Age: A Report from the Center for International Blood and Marrow Transplant Research. Tandem Meeting. 2016; Abstract.

Progressive Lung Disease Is A Key Feature of Late Onset RAG Deficiency. ESID Meeting. 2016; Abstract.

Aldrich Syndrome: A Retrospective Study on 575 Patients Analyzing the Impact of Splenectomy, Stem Cell Transplantation, or No Definite Treatment on Frequency of Disease-related Complications and Physician-perceived Quality of Life. ASH Meeting. 2016; Abstract.

Publications

Buchbinder D, Casillas J, Krull KR, Goodman P, Leisenring W, Recklitis C, Alderfer MA, Robison LL, Armstrong GT, Kunin-Batson A, Stuber M, Zeltzer LK. Psychological Outcomes of Siblings of Cancer Survivors: A Report from the Childhood Cancer Survivor Study. PsychoOncology 2010 (In Press).

Buchbinder D, Nugent D, Vu D, Soni A, Stites J, Hsieh L, Puthenveetil G. Unrelated Hematopoietic Stem Cell Transplantation in a Patient with Congenital Dyserythropoietic Anemia and Iron Overload. Pediatr Transplant. 2010 Nov 26. doi: 10.1111/j.1399-3046.2010.01414.x. [Epub ahead of print]

Buchbinder D, Casillas J, Zeltzer LK. Meeting the Psychological Needs of Siblings Survivors: A Family Systems Approach. J Pediatr Oncol Nurs. 2010 Nov 22. [Epub ahead of print]

Buchbinder D, Steinberg G, Linetsky M, Casillas J. Moyamoya in a Child Treated with Interferon for Recurrent Osteosarcoma. J Pediatr Hematol Oncol. 2010 Aug;32(6):476-8.

Buchbinder D, Danielpour M, Yong M, Salamon N, Lasky J. Treatment of Atypical Central Neurocytoma in a Child With High Dose Chemotherapy and Autologous Stem Cell Rescue. J Neurooncol. 2010 May;97(3):429-37. Epub 2009 Nov 19.

Buchbinder D, Levi DS, Ikeda A, Shannon K, Moore TB. Inappropriate Sinus Tachycardia Following Hematopoietic Stem Cell Transplantation. JPHO 2010; 32(1):15-18.

Zeltzer LK, Recklitis C, Buchbinder D, Zebrack B, Casillas J, Tsao JC, Lu Q, Krull K. Psychological status in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2009; 27(14): 2396-404. Buchbinder D, Shabani-Rad MT, Schiepers C, Moore T. A child who refuses to ambulate. Clinical Pediatrics 2009; 48(4): 452-5.

Buchbinder D, et al. Broad spectrum of autoantibodies in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopenia. J Allergy Clin Immunol. 2015; 136(5):1401-1404.e3.

Buchbinder D, et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest. 2015; 125(11):4135-48.

Buchbinder D, et al. Tobacco Use Among Siblings of Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2016; 63(2):326-33.

Research Bio

Dr. Buchbinder’s clinical and research interests are in hematopoietic cell transplantation for non-malignant disorders, in addition to investigating and understanding psychosocial impact of chronic illness in patients and families. He is currently working with his colleagues at CHOC and the University of California, Irvine to look at the impact of late occurring toxicities of hematopoietic and malignant diseases.

Our hematologists commonly treat:

  • Anemia, including sickle cell anemia, thalassemia, iron deficiency and lead toxicity
  • White cell and immune deficiency disorders
  • Aplastic anemia
  • Bone marrow failure syndromes
  • Thrombocytopenia
  • Vascular malformation/hemangiomas
  • Platelet disorders
  • Coagulation abnormalities, hemophilia,  Von Willebrand’s disease, rare bleeding disorders such as Factor 13 deficiency
  • Excessive clotting disorders,  thrombophilia, deep venous clots, pulmonary embolus or stroke
  • Acquired bleeding and clotting disorders
  • Prevention of bleeding and clotting problems, with particular experience for patients on cardiopulmonary bypass